Subunit vaccines with a saponin-based adjuvant boost humoral and cellular immunity to MERS coronavirus.

Autor: Chang CC; Institute of Biochemistry and Molecular Biology, College of Medicine, National Taiwan University, Taipei 10051, Taiwan., Algaissi A; Department of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, TX 77555, USA; Center for Biodefense and Emerging Disease, The University of Texas Medical Branch, Galveston, TX 77555, USA., Lai CC; National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli County 35053, Taiwan; College of Life Science, National Tsing Hua University, Hsinchu 30013, Taiwan., Chang CK; School of Pharmacy, College of Medicine, National Taiwan University, Taipei 100025, Taiwan., Lin JS; Graduate Institute of Immunology, College of Medicine, National Taiwan University, Taipei 10051, Taiwan., Wang YS; Institute of Biochemistry and Molecular Biology, College of Medicine, National Taiwan University, Taipei 10051, Taiwan., Chang BH; Institute of Biochemistry and Molecular Biology, College of Medicine, National Taiwan University, Taipei 10051, Taiwan., Chang YC; Institute of Biochemistry and Molecular Biology, College of Medicine, National Taiwan University, Taipei 10051, Taiwan., Chen WT; Department of Physics, National Taiwan University, Taipei 10617, Taiwan., Fan YQ; Institute of Biochemistry and Molecular Biology, College of Medicine, National Taiwan University, Taipei 10051, Taiwan., Peng BH; Department of Neurosciences, The University of Texas Medical Branch, Galveston, TX 77555, USA., Chao CY; Department of Physics, National Taiwan University, Taipei 10617, Taiwan., Tzeng SR; Institute of Biochemistry and Molecular Biology, College of Medicine, National Taiwan University, Taipei 10051, Taiwan., Liang PH; School of Pharmacy, College of Medicine, National Taiwan University, Taipei 100025, Taiwan., Sung WC; National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli County 35053, Taiwan., Hu AY; National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli County 35053, Taiwan., Chang SC; Institute of Microbiology, College of Medicine, National Taiwan University, Taipei 10051, Taiwan., Chang MF; Institute of Biochemistry and Molecular Biology, College of Medicine, National Taiwan University, Taipei 10051, Taiwan. Electronic address: mfchang@ntu.edu.tw.
Jazyk: angličtina
Zdroj: Vaccine [Vaccine] 2023 May 16; Vol. 41 (21), pp. 3337-3346. Date of Electronic Publication: 2023 Apr 10.
DOI: 10.1016/j.vaccine.2023.04.006
Abstrakt: Middle East respiratory syndrome coronavirus (MERS-CoV) outbreaks have constituted a public health issue with drastic mortality higher than 34%, necessitating the development of an effective vaccine. During MERS-CoV infection, the trimeric spike protein on the viral envelope is primarily responsible for attachment to host cellular receptor, dipeptidyl peptidase 4 (DPP4). With the goal of generating a protein-based prophylactic, we designed a subunit vaccine comprising the recombinant S1 protein with a trimerization motif (S1-Fd) and examined its immunogenicity and protective immune responses in combination with various adjuvants. We found that sera from immunized wild-type and human DPP4 transgenic mice contained S1-specific antibodies that can neutralize MERS-CoV infection in susceptible cells. Vaccination with S1-Fd protein in combination with a saponin-based QS-21 adjuvant provided long-term humoral as well as cellular immunity in mice. Our findings highlight the significance of the trimeric S1 protein in the development of MERS-CoV vaccines and offer a suitable adjuvant, QS-21, to induce robust and prolonged memory T cell response.
Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Ming-Fu Chang reports financial support was provided by Ministry of Science & Technology of Taiwan. Ming-Fu Chang reports a relationship with Ministry of Science & Technology of Taiwan that includes: funding grants. Ming-Fu Chang has patent NA pending to NA. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: